MA26752A1 - Composes de quinoleine, leurs preparations et leurs utilisations therapeutiques. - Google Patents

Composes de quinoleine, leurs preparations et leurs utilisations therapeutiques.

Info

Publication number
MA26752A1
MA26752A1 MA26068A MA26068A MA26752A1 MA 26752 A1 MA26752 A1 MA 26752A1 MA 26068 A MA26068 A MA 26068A MA 26068 A MA26068 A MA 26068A MA 26752 A1 MA26752 A1 MA 26752A1
Authority
MA
Morocco
Prior art keywords
phenyl
lower alkyl
amino
hydrogen atom
alkyl group
Prior art date
Application number
MA26068A
Other languages
English (en)
Inventor
Alanine Alexander
Burner Serge
Heitz Neidhart Marie-Paule
Jaeschke Georg
Wyler Rene
Buettelmann Bernd
Pinard Emmanuel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26752A1 publication Critical patent/MA26752A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composés de quinoléine, leurs préparations et leurs utilisations thérapeutiques F. HOFFMANN-LA ROCHE AG 1. Composés de formule dans laquelle R1 est un atome d'hydrogène, un groupe alkyle inférieur, alcoxy inférieur, hydroxy, amino, nitro, cyano, (alkyle inférieur)amino, (dialkyle inférieur)amino, ou un atome d'halogène; R2 est un groupe phényle, éventuellement substitué par un groupe alkyle inférieur, alcoxy inférieur, un atome d'halogène, un groupe trifluorométhyle, amino, (alkyle inférieur)amino ou (dialkyle inférieur)amino, 2,3-dihydro-benzofuran-5-yle, chroman-6-yle, naphtalén-2-yle, indan-5-yle, (alcényle inférieur)phényle, 5,6,7,8-tétrahydro-naphtalényle, 2,3-dihydro-isoindol-2-yle, 1,2,3,4-tétraydro-naphtalényle, benzofuran-2-yle, benzo[b]thiophén-2-yle, (alkyle inférieur)phényle, 3,4-dihyro-1H-isoquinoléin-2-yle ou thiophén-3-yle; R3 et R4 sont indépendamment l'un de l'autre un atome d'hydrogène ou un groupe alkyle inférieur; R5 est un atome d'hydrogène, un groupe alkyle inférieur, -CH2OH ou -CH2NR6R7; R6 et R7 sont indépendamment l'un de l'autre un atome d'hydrogène, un groupe alkyle inférieur, -(CH2)n-phényle, cycloalkyle, -(CH2)m-morpholinyle ou forment ensemble avec l'atome N un cycle saturé avec 4 à 6 atomes de carbone; n vaut de 0 à 3; m vaut 2 ou 3; X est -NR8- ou -O-; ou X et R5 sont ensemble >N(CH2)2-; ou X et R3 sont ensemble >N(CH2)3-; et R8 est un atome d'hydrogène ou un groupe alkyle inférieur; et à leurs sels d'addition d'acide acceptables sur le plan pharmaceutique, à l'exception des composés suivants : le (6-chloro-2-phényl-4-quinolinyl)-(+)-2-aminobutanol; le (6-méthyl-2-phényl-4-quinolinyl)-(+)-2-aminobutanol; le (6-méthoxy-2-phényl-4-quinolinyl)-(+)-2-aminobutanol; et le (8-méthoxy-2-phényl-4-quinolinyl)-(+)-2-aminobutanol, qui peuvent être utilisés pour le traitement de maladies, en relation avec des bloquants spécifiques de récepteur NMDA.
MA26068A 1999-10-01 2000-09-26 Composes de quinoleine, leurs preparations et leurs utilisations therapeutiques. MA26752A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99119539 1999-10-01

Publications (1)

Publication Number Publication Date
MA26752A1 true MA26752A1 (fr) 2004-12-20

Family

ID=8239107

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26068A MA26752A1 (fr) 1999-10-01 2000-09-26 Composes de quinoleine, leurs preparations et leurs utilisations therapeutiques.

Country Status (26)

Country Link
US (1) US6440995B1 (fr)
JP (1) JP3523174B2 (fr)
KR (1) KR100398561B1 (fr)
CN (1) CN1181059C (fr)
AR (1) AR025882A1 (fr)
AT (1) ATE281436T1 (fr)
AU (1) AU774363B2 (fr)
BR (1) BR0004548A (fr)
CA (1) CA2321324A1 (fr)
CO (1) CO5200789A1 (fr)
CZ (1) CZ20003575A3 (fr)
DE (1) DE60015471T2 (fr)
ES (1) ES2230017T3 (fr)
HR (1) HRP20000639A2 (fr)
HU (1) HUP0003861A3 (fr)
ID (1) ID27525A (fr)
IL (1) IL138777A0 (fr)
MA (1) MA26752A1 (fr)
NO (1) NO20004892L (fr)
NZ (1) NZ507141A (fr)
PE (1) PE20010648A1 (fr)
PL (1) PL342876A1 (fr)
PT (1) PT1088818E (fr)
SG (1) SG164268A1 (fr)
TR (1) TR200002831A3 (fr)
ZA (1) ZA200005239B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831087B2 (en) * 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
KR100618752B1 (ko) * 2002-02-13 2006-08-31 에프. 호프만-라 로슈 아게 신규한 피리딘- 및 퀴놀린-유도체
US7648984B2 (en) * 2004-07-13 2010-01-19 Glaxo Group Limited Antibacterial agents
EP2573080A1 (fr) * 2007-09-27 2013-03-27 The United States of America, as Represented by the Secretary, Department of Health and Human Services Composés d'Isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
CA2987978C (fr) * 2014-06-16 2022-08-16 Fundacion Para La Investigacion Medica Aplicada Nouveaux composes utilises comme inhibiteurs doubles d'histone methyltransferases et d'adn methyltransferases
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
KR20170074178A (ko) * 2015-12-21 2017-06-29 제이엔씨 주식회사 중합성 액정 화합물, 조성물, 그 액정 중합막류 및 이들의 용도
CN105646462B (zh) * 2016-01-19 2019-04-05 河南大学 芸香宁碱衍生物、其制备方法及应用
WO2018204176A1 (fr) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibiteurs de la protéine tyrosine phosphatase de faible poids moléculaire (lmptp) et utilisations associées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE440008C (de) 1924-03-29 1927-05-04 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Chinolinderivaten
US4560692A (en) 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5441963A (en) 1991-12-20 1995-08-15 Merrell Dow Pharmaceuticals Potentiation of NMDA antagonists

Also Published As

Publication number Publication date
HU0003861D0 (en) 2000-12-28
AU774363B2 (en) 2004-06-24
KR100398561B1 (ko) 2003-09-19
HUP0003861A3 (en) 2002-09-30
ES2230017T3 (es) 2005-05-01
JP2001097952A (ja) 2001-04-10
KR20010050738A (ko) 2001-06-15
HUP0003861A2 (hu) 2001-10-28
DE60015471T2 (de) 2005-10-27
ATE281436T1 (de) 2004-11-15
US6440995B1 (en) 2002-08-27
TR200002831A2 (tr) 2001-04-20
CN1290698A (zh) 2001-04-11
CO5200789A1 (es) 2002-09-27
PT1088818E (pt) 2005-03-31
CA2321324A1 (fr) 2001-04-01
NO20004892D0 (no) 2000-09-29
BR0004548A (pt) 2001-05-29
SG164268A1 (en) 2010-09-29
CZ20003575A3 (cs) 2001-11-14
JP3523174B2 (ja) 2004-04-26
AU6132400A (en) 2001-04-05
ID27525A (id) 2001-04-12
CN1181059C (zh) 2004-12-22
NZ507141A (en) 2002-05-31
TR200002831A3 (tr) 2001-04-20
PL342876A1 (en) 2001-04-09
DE60015471D1 (de) 2004-12-09
AR025882A1 (es) 2002-12-18
ZA200005239B (en) 2001-04-16
HRP20000639A2 (en) 2001-06-30
IL138777A0 (en) 2001-10-31
NO20004892L (no) 2001-04-02
PE20010648A1 (es) 2001-06-13

Similar Documents

Publication Publication Date Title
MA26722A1 (fr) Nouveaux composes et medicaments les contenant
MXPA02008770A (es) Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina.
MA28008A1 (fr) Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
MA27119A1 (fr) Modulateurs tetrahydropyranyle cyclopentyle tetrahydropyrido pyridine de l'activite d'un recepteur de chimiokine
MA26752A1 (fr) Composes de quinoleine, leurs preparations et leurs utilisations therapeutiques.
KR880012227A (ko) 도파민 수용체 길항제의 신규사용법
SE8800638L (sv) Antihypercholesterolemic tetrazole compounds
FR2394542A1 (fr) Derives de 3-(1-pyrazolyl)-pyridazine et leur procede de preparation et nouveaux medicaments les contenant
NO168582C (no) Analogifremgangsmaate for fremstilling av nye, terapeutiskvirksomme dihydrobenzofuran- og chroman-carboxamidderivater
MA27492A1 (fr) Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
DE3462894D1 (de) 3-indolecarboxamide compounds
PT1080081E (pt) Derivados do benzofuraxano e a sua utilizacao no tratamento da angina de peito
FR2858321B1 (fr) Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PE20040668A1 (es) Nuevos derivados de piperidina
DE69005974T2 (de) Heteroaryl-3-oxo-propannitril-derivate, nützlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
BE900178A (fr) Urees et thio-urees anti-atherosclerotiques.
MA26721A1 (fr) Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2403336A1 (fr) Derives de 3,4-dihydrocarbostyrile, leur procede de preparation et leur utilisation pour le traitement des troubles cardiaques
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
DE60130628D1 (de) Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen
ATE123487T1 (de) Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen.
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
BE1002181A3 (fr) 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines, de meme que le traitement de la leucemie et des tumeurs avec ces substances.
MXPA02005088A (es) Tratamiento de trastornos del ritmo cardiaco con n6-substituida-5'(n-substituida) carboxamidoadenosinas.
MA24904A1 (fr) Procede de preparation d'intermediaires pesticides